Project Grant HT94252410674
Award Date
6/30/24
Completion Date
6/29/27
Dollars Obligated
$767K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
The University of Texas Southwestern Medical Center (UT Southwestern) has been awarded a Project Grant for $1,180,962.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on June 30, 2024, will support a research project titled "TUMOR SURFACE BIOMARKER-INDEPENDENT TARGETING OF KIDNEY CANCER TO IMPROVE IMMUNOTHERAPY" over a performance period ending on June 29, 2027. The grant funding will enable UT...
The Defense Health Agency awarded a $1.1 million project grant to the University of Texas Southwestern Medical Center in Dallas, Texas, to support research under the Military Medical Research and Development program. The three-year award beginning in June 2023 will fund the development of a multifunctional immunotherapy nanoparticle to enable innate immunotherapy for kidney cancer. As the prime awardee, UT Southwestern will leverage its expertise in oncology and immunology to advance this...
The University of Texas Southwestern Medical Center (UT Southwestern) was awarded a $713,689 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The three-year grant, effective September 1, 2023, will support UT Southwestern's research to leverage biophysicochemical motifs in T-cell receptor antigen binding regions and antigen co-occurrence to predict response to immune checkpoint inhibitors. The grant provides funding for basic...
The University of Texas Southwestern Medical Center (UT Southwestern) was awarded a $1,083,136 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support research from August 15, 2023 through August 14, 2026 to leverage SCARB1 overexpression for the treatment of clear cell renal cell carcinoma (CCRCC) using low-density lipoprotein nanocarriers. UT Southwestern has extensive experience delivering...
The University of Texas Southwestern Medical Center (UT Southwestern) was awarded a $319,798 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) on April 15, 2024. The grant supports UT Southwestern's research to dissect unconventional mechanisms of action and resistance to rapalogs, a class of drugs, in renal cell carcinoma. The research aims to make significant advances in military medicine by improving...
The University of Texas Southwestern Medical Center (UT Southwestern) was awarded a $1,107,000 project grant from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) to conduct research on tumor extravasation in zebrafish as a prognostic marker and therapeutic target for kidney cancer metastasis. The 3-year grant, which began on September 1, 2023 and runs through August 31, 2026, will support basic, applied, and advanced biomedical research with the...
This $1,189,000.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) aims to target stem-like CD8 T cells in immunotherapy against kidney cancer. The grant was awarded on September 1, 2023 to The University of Texas Southwestern Medical Center, an academic medical institution and component of the University of Texas System, to be completed by August 31, 2027. Through this funding, UT Southwestern will conduct research...
The University of Texas Southwestern Medical Center was awarded a $984,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "Ribosome Marylation and Stress Responses in Ovarian Cancer: New Therapeutic Opportunities". The 3-year grant, effective September 1, 2024, will support basic science, translational, and clinical research to investigate new treatment approaches for ovarian cancer. As a...
The University of Texas Southwestern Medical Center (UT Southwestern) was awarded a $324,452 Project Grant under the Military Medical Research and Development program (CFDA 12.420) by the Defense Health Agency. The grant, titled "Targeting PARP1 Trapping to Overcome PARP Inhibitor Resistance for BRCAmut Ovarian Cancers," will support research aimed at developing new treatments for ovarian cancer in military populations. The funding will enable UT Southwestern, a leading academic...
The Defense Health Agency awarded a $1,107,001 Project Grant to The University of Texas Southwestern Medical Center (UT Southwestern) to conduct research on the DROSHA gene's role in regulating mesenchymal expression and chemosensitivity in Wilms tumor. The grant was awarded on September 30, 2023 and will run through September 29, 2026 under the Military Medical Research and Development program (CFDA 12.420). UT Southwestern, a component of the University of Texas System, will lead the...